2020
DOI: 10.1016/j.jgar.2019.07.026
|View full text |Cite
|
Sign up to set email alerts
|

Oral antibiotics for the treatment of Gram-negative bloodstream infections: A retrospective comparison of three antibiotic classes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
13
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 22 publications
(16 citation statements)
references
References 13 publications
3
13
0
Order By: Relevance
“…Moreover, the increase in antibiotic-resistant phenotypes and antibiotic resistance genes in different environments [ 22 ] and widely different organisms [ 23 ] requires urgent identification and development, at an industrial level, of new antimicrobial solutions. In this context, highly desirable new anti-pseudomonal and -staphylococcal antimicrobials should not drive superinfection [ 20 ] and be preferably available as oral formulations to allow step-down therapy in the treatment of both Gram-negative and -positive infections [ 24 ].…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, the increase in antibiotic-resistant phenotypes and antibiotic resistance genes in different environments [ 22 ] and widely different organisms [ 23 ] requires urgent identification and development, at an industrial level, of new antimicrobial solutions. In this context, highly desirable new anti-pseudomonal and -staphylococcal antimicrobials should not drive superinfection [ 20 ] and be preferably available as oral formulations to allow step-down therapy in the treatment of both Gram-negative and -positive infections [ 24 ].…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, the increase of antibiotic-resistant phenotypes and antibiotic resistance genes in different environments [22] and widely different organisms [23], requires to urgently identify and develop at an industrial level new antimicrobial solutions against said pathogens. In this context, highly desirable new anti-pseudomonal andstaphylococcal antimicrobials should not drive superinfection [20], and be preferably available as oral formulations to allow step-down therapy in the treatment of both Gram-negative and -positive infections [24].…”
Section: Introductionmentioning
confidence: 99%
“…Although, oral antibiotics have been successfully used in the treatment of bacterial infection, for P. aeruginosa few therapeutic options are available, being restricted to some fluoroquinolones, including ciprofloxacin, levofloxacin, and prulifloxacin, which are given alone or in combinations with a second intravenously or inhaled anti-pseudomonal antibiotic such as β-lactams (piperacillin/tazobactam, ceftolozane/ tazobactam, ceftazidime, cefepime, or carbapenems) and/or aminoglycosides (tobramycin, amikacin, or gentamicin) (Tümmler, 2019;Ibrahim et al, 2020;Nisly et al, 2020). However, under a clinical perspective, even co-resistance to carbapenems and aminoglycosides in ST277 have already been reported and limited therapeutic options.…”
Section: Discussionmentioning
confidence: 99%